Beta

Kyntra bio, inc.KYNB.US Overview

US StockHealthcare
(No presentation for KYNB)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

KYNB AI Insights

KYNB Overall Performance

KYNB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KYNB Recent Performance

0.28%

Kyntra bio, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

KYNB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check KYNB's Trend

KYNB Key Information

KYNB Valuation Metrics

KYNB Profile

Price of KYNB

KYNB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KYNB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
46.06
PE Ratio (TTM)
-
Forward PE
61.35
PS Ratio (TTM)
4.49
PB Ratio
80.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
90.65%
Net Margin
7922.48%
Revenue Growth (YoY)
-42.43%
Profit Growth (YoY)
-43.12%
3-Year Revenue Growth
-73.20%
3-Year Profit Growth
-66.49%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
46.06
PE Ratio (TTM)
-
Forward PE
61.35
PS Ratio (TTM)
4.49
PB Ratio
80.40
Price-to-FCF
-
Gross Margin
90.65%
Net Margin
7922.48%
Revenue Growth (YoY)
-42.43%
Profit Growth (YoY)
-43.12%
3-Year Revenue Growth
-73.20%
3-Year Profit Growth
-66.49%

  • When is KYNB's latest earnings report released?

    The most recent financial report for Kyntra bio, inc. (KYNB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KYNB's short-term business performance and financial health. For the latest updates on KYNB's earnings releases, visit this page regularly.

  • What is the operating profit of KYNB?

    According to the latest financial report, Kyntra bio, inc. (KYNB) reported an Operating Profit of -13.51M with an Operating Margin of -1,058.1% this period, representing a growth of 85.26% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is KYNB's revenue growth?

    In the latest financial report, Kyntra bio, inc. (KYNB) announced revenue of 1.28M, with a Year-Over-Year growth rate of 101.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does KYNB have?

    At the end of the period, Kyntra bio, inc. (KYNB) held Total Cash and Cash Equivalents of 47.87M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does KYNB go with three margins increasing?

    In the latest report, Kyntra bio, inc. (KYNB) did not achieve the “three margins increasing” benchmark, with a gross margin of 78.2%%, operating margin of -1,058.1%%, and net margin of -1,113.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess KYNB's profit trajectory and future growth potential.

  • Is KYNB's EPS continuing to grow?

    According to the past four quarterly reports, Kyntra bio, inc. (KYNB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KYNB?

    Kyntra bio, inc. (KYNB)'s Free Cash Flow (FCF) for the period is -18.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 39.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of KYNB?

    The latest valuation data shows Kyntra bio, inc. (KYNB) has a Price-To-Earnings (PE) ratio of 0.15 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.